Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 16,841 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Disease Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Messaging for Vaccination

NCT05182554
View directory record Official record
Conditions
Vaccination Refusal, COVID-19 Pandemic
Interventions
Doctor Videos, Sharing Videos, Sharing Videos (Influencers), Vaccine Ambassador, Video framing, Video order
Behavioral
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Not applicable Interventional

Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions

NCT01431183
View directory record Official record
Conditions
Seasonal Influenza Vaccination
Interventions
Mailed influenza vaccination reminder notice
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
24 Months to 60 Months
Enrollment
3,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2011 · Synced Oct 11, 2026, 5:59 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Tfh Dysfunction in HIV and Aging

NCT04487041
View directory record Official record
Conditions
Human Influenza
Interventions
Standard dose influenza vaccination, High dose influenza vaccination
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Terminated Not applicable Interventional Results available

Impact of Respiratory Training in Lymphoma Survivors

NCT05938127
View directory record Official record
Conditions
Hodgkin Lymphoma, Non Hodgkin Lymphoma
Interventions
Inspiratory muscle strength training, Sham Inspiratory muscle strength training
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

, "Mucosal Injury During Nasotracheal Intubation for Dental Procedures in Children-does the Tube Design Matter?"

NCT02517294
View directory record Official record
Conditions
Epistaxis
Interventions
Parker flex-tip nasotracheal tube, Standard nasotracheal tube
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years to 11 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

NCT02713529
View directory record Official record
Conditions
Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer
Interventions
AMG820 and pembrolizumab
Biological
Lead sponsor
AmMax Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 11, 2026, 5:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 11, 2026, 5:59 AM EDT
Completed No phase listed Observational

Physical Activity Intervention for Lung Cancer Survivors

NCT00717795
View directory record Official record
Conditions
Lung Cancer, Survivor
Interventions
interview and physical activity, interview and wait list
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 11, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777
View directory record Official record
Conditions
Cough, Refractory Chronic Cough
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 80 Years
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
57
States / cities
Foley, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

NCT03916419
View directory record Official record
Conditions
Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
Interventions
ViewRay MR-Linear Accelerator, Radiation therapy, Paclitaxel, Carboplatin AUC, Durvalumab
Device · Radiation · Drug + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)

NCT00958919
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
naloxone, normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 11, 2026, 5:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Erythromycin in GER-Associated Apnea of the Newborn

NCT01825473
View directory record Official record
Conditions
Gastroesophageal Reflux, Apnea, Bradycardia
Interventions
Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W)
Drug · Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Days and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 11, 2026, 5:59 AM EDT
Suspended Phase 1Phase 2 Interventional

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT06694454
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions
azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Attitudes About Smoking: A Telephone Survey

NCT00156494
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 60 Years
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 11, 2026, 5:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer

NCT00004137
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, paclitaxel, topotecan hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 11, 2026, 5:59 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

NCT07554339
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Calderasib, Durvalumab, Placebo to MK-1084
Drug · Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
5
States / cities
Lisle, Illinois • Lincoln, Nebraska • Albany, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Not applicable Interventional

Nocturnal Hypertension and Non-Dipping Blood Pressure

NCT03128177
View directory record Official record
Conditions
Hypertension, Obstructive Sleep Apnea
Interventions
Dietary sodium
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
48 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 11, 2026, 5:59 AM EDT
Completed No phase listed Observational

Cough in Reduced True Vocal Fold Mobility

NCT02407301
View directory record Official record
Conditions
Unilateral Vocal Cord Paresis, Unilateral Vocal Cord Paralysis
Interventions
cough airflow measure, vocal tasks, true vocal fold movement, spirometry test, maximum expiratory pressure (MEP)
Other
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Improving Asthma Communication in Minority Families

NCT00133666
View directory record Official record
Conditions
Asthma
Interventions
Asthma Communication Education, Standard Asthma Education
Behavioral
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
6 Years to 12 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Oct 11, 2026, 5:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

NCT03974022
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sunvozertinib
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 11, 2026, 5:59 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions

NCT01878929
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Allergic Conjunctivitis
Interventions
Allergen(Tree, Grass, Weeds)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
South Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 11, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 11, 2026, 5:59 AM EDT